

## Special Issue

# Inequality in Immunization 2025

### Message from the Guest Editors

Significant progress has been made in improving access to immunization worldwide, particularly for children. However, the benefits of increased vaccine access are not evenly distributed within or across countries. Research and monitoring have identified persistent and emerging gaps in both childhood and adult immunization, influenced by factors such as socioeconomic status, place of residence, and gender. These have been examined in previous Special Issues of *Vaccines* in 2023 and 2024, which showcased advancements in our understanding of immunization inequalities and presented options for immunization delivery that offer promise in addressing disparities. Emerging challenges like vaccine refusal and hesitancy exacerbate vaccine inequalities during times of reform, stability, and crisis. In the latest Special Issue on Inequality in Immunization, the third in our series, we aim to expand the existing body of evidence. We welcome research and review articles that explore immunization inequalities and articles that effectively address these inequities in meaningful and lasting ways.

---

### Guest Editors

Dr. Ahmad Reza Hosseinpoor

Dr. Devaki Nambiar

Dr. Nicole Bergen

Dr. M. Carolina Danovaro

Dr. Hope L. Johnson

Dr. Ibrahim Dadari

---

### Deadline for manuscript submissions

closed (15 September 2025)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/227993](https://mdpi.com/si/227993)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).